Fujisawa Pharmaceutical of Japan has announced a two-step plan toreorganize its European operations in a bid to improve operational efficiency and profitability and establish a stronger presence in German-speaking countries.
In the first stage, Fujisawa Europe, previously a holding company for Klinge Pharma and Fujisawa GmbH, has merged with the latter company and will operate under the Fujisawa GmbH moniker. The new entity will function as the group's European headquarters and as the parent of Klinge and other marketing subsidiaries.
The second phase of the reorganization plan, which will be effective January 1, 2002, will see Fujisawa GmbH acquire the remaining minority stake in Klinge (9.5%) in order to make it a wholly-owned subsidiary. Klinge will subsequently change its name, probably to Fujisawa Deutscheland GmbH, and operate as a sales and marketing arm covering both the general practitioner and hospital markets in German-speaking countries in Europe. Klinge's R&D activities will be scaled down.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze